Free tracked shipping
LYZE LABS
Lyze Labs Trevogrumab 0.1 mg - Verified >99% Purity HPLC Research Standard
Growth hormone

Trevogrumab

Trevogrumab (REGN1033) is a fully human anti-myostatin antibody for muscle research. Sold per vial, 0.1 mg to 100 mg; no GDF11 cross-reactivity.

Single vialFreeze-dried powder4.8 on Trustpilot

Also known as REGN1033

For research and laboratory use only. Not for human consumption.

$720a vial

Strength per vial
Choose how many vials

Mix any kits. Every kit in your cart counts toward the price. More than 50, or a custom size? Ask for a quote

1
Batch
Delivery
Free tracked shipping to 150+ countries. Delivery guaranteed. How delivery works
Report
98.9% Purity Verified · SEC-HPLC / SDS-PAGE / Intact Mass / ELISA Tested · Delivery photos
Guarantee
If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.
Help
A person answers on WhatsApp, even at 3 a.m. your time.

Trevogrumab: Key Facts

Trevogrumab is a muscle growth research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 5 formats. Each batch is independently HPLC-verified at 98.9% purity by Janoshik Analytical, with the certificate of analysis for the batch we're shipping now published on the lab-results page.

Third-party verified batch

CompoundTrevogrumab
Research categoryGrowth hormone
Available formats0.1mg x 1 vial, 1mg x 1 vial, 5mg x 1 vial, 10mg x 1 vial, 100mg x 1 vial
Strength shown0.1 mg
Molecular formulaC₆₃₇₄H₉₈₈₄N₁₆₉₆O₂₀₁₈S₄₆
Molecular weight144,037.80 g/mol (~144 kDa)
CAS number1429201-24-0
BatchLZ-TRV-261004
Purity98.9% verified (third-party HPLC, Janoshik)
Test methodSEC-HPLC / SDS-PAGE / Intact Mass / ELISA
Certificate of analysisPublished online for the batch we're shipping now
Intended useLaboratory research use only. Not for human consumption.
HandlingSupplied lyophilized, store per the stability guide

Good to know

The report is online before you order. Check the batch and its test date, then decide.

Your price drops with every kit. Any mix counts, up to 42% off at 50 kits.

What Researchers Say

Read All Reviews

Independent research lab

United States

"Ordered the 1mg for a myostatin neutralisation assay. SEC trace on the certificate matched what we measured in-house, monomer just over 99 percent. Good to see a vendor that does not call this a peptide."

2026-08-06

Daniel K.

Germany

"Arrived intact in 11 days. Reconstituted clear, no visible particulates."

2026-08-04

Independent testing lab

United Kingdom

"The GDF11 counter-screen row on the COA is the reason we bought here rather than a decoy receptor. The certificate was online before we ordered."

2026-08-01

About This Product

Trevogrumab (REGN1033) Research Guide

What is Trevogrumab?

Trevogrumab is a fully human IgG4-kappa monoclonal antibody that binds and neutralises myostatin, also called growth differentiation factor 8 or GDF-8. Its development code is REGN1033. It was generated by Regeneron on the VelocImmune platform, with Sanofi as a development partner, and it is in Phase 2 clinical investigation in the COURAGE trial (NCT06299098) combined with semaglutide for lean mass preservation during weight loss.

Key identifiers: CAS 1429201-24-0, molecular formula C6374H9884N1696O2018S46, molar mass 144,037.80 g/mol, roughly 144 kDa. Expressed in Chinese hamster ovary cells and purified by Protein A affinity chromatography.

Trevogrumab is not a peptide. It is a four-chain antibody about thirty times the mass of a peptide like BPC-157, with two heavy chains, two light chains, interchain disulfide bonds and N-linked glycosylation. Solid-phase peptide synthesis cannot produce it. Several vendors list it under "peptides" anyway; that labelling is wrong and it changes how the material must be tested, stored and handled.

How does Trevogrumab work?

Myostatin is the principal negative regulator of skeletal muscle mass. It is secreted by myocytes, circulates as a latent complex, and signals through the activin type IIB receptor (ActRIIB) paired with ALK4 or ALK5, driving SMAD2 and SMAD3 phosphorylation and restraining muscle protein synthesis.

Trevogrumab is a ligand trap. It binds myostatin in the extracellular space and prevents it engaging ActRIIB, rather than blocking the receptor itself.

  • Binds all three forms: mature myostatin, the latent complex, and the pro-form
  • Does not cross-react with GDF11, despite roughly 90 percent mature-domain identity
  • IgG4 backbone: minimal Fc effector function, so a neutralising antibody does not also recruit antibody-dependent cytotoxicity
  • Ligand trap, not receptor blocker: leaves ActRIIB free for its other ligands, which is a cleaner design when the study variable is myostatin specifically

Why does the GDF11 selectivity matter?

Most myostatin tools cannot tell myostatin and GDF11 apart. A soluble ActRIIB-Fc decoy binds myostatin, GDF11, activin A and several BMPs at once, so any phenotype it produces is the sum of all of them and no downstream analysis separates the contributions afterwards.

An antibody selective for myostatin over GDF11 lets a research model attribute an effect to one ligand. If a study design depends on that attribution, this is the reason to choose Trevogrumab over a decoy receptor construct, and it belongs in the methods section.

What did the COURAGE trial show?

COURAGE (NCT06299098) is Regeneron's Phase 2 study of semaglutide combined with trevogrumab, with or without Garetosmab. Results were presented at the EASD 2025 Annual Meeting.

The trial first quantified the problem: roughly one third of the weight lost on semaglutide alone was lean mass, not fat.

Change in lean body mass from baseline at 26 weeks:

  • Semaglutide alone: -6.5%
  • Semaglutide + trevogrumab (two strengths): -3.3% and -3.8%
  • Semaglutide + trevogrumab + garetosmab: -2.0%

The triplet reached 80.9 percent lean mass preservation and a 27.3 percent increase in fat mass reduction compared with semaglutide alone.

On tolerability, semaglutide plus trevogrumab was generally well tolerated. The triplet combination, which adds garetosmab, had a substantially higher rate of discontinuations for tolerability and other adverse events. Adverse events reported in at least 5 percent of any group included muscle spasms, nausea, constipation, fatigue, diarrhoea, headache, vomiting, gastro-oesophageal reflux, upper respiratory tract infection, nasopharyngitis, urinary tract infection, influenza and COVID-19.

Trevogrumab is investigational. It is not approved as a medicine in any jurisdiction.

How does Trevogrumab compare to bimagrumab and apitegromab?

These are the three antibodies driving myostatin-pathway research in 2026, and they work at different points in the same pathway. Full breakdown in the myostatin inhibitor comparison guide.

  • Trevogrumab: myostatin (GDF-8), at the ligand. Binds mature, latent and pro-forms; no GDF11 cross-reactivity.
  • Garetosmab: activin A, AB and AC, at the ligand. Does not bind activin B, inhibin A, BMP-2/6/9/10, GDF8 or GDF11.
  • Bimagrumab: ActRIIA and ActRIIB, at the receptor. Blocks the whole receptor, so myostatin and activin A together.
  • Apitegromab: pro- and latent myostatin, the ligand precursor. Ignores mature myostatin entirely, the narrowest window of the four.

The practical difference: a receptor blocker produces the largest effect and the least attribution, a ligand trap produces a smaller effect you can actually assign to one ligand. In BELIEVE, bimagrumab produced a 2.5 percent increase in lean mass where semaglutide alone produced a 7.4 percent loss.

Research applications

  • Myostatin and GDF-8 pathway pharmacology in skeletal muscle models
  • SMAD2 and SMAD3 signalling studies requiring selective ligand neutralisation
  • Separating myostatin-driven from GDF11-driven effects, which broad ActRIIB traps cannot do
  • Lean mass preservation research alongside incretin agonists such as Semaglutide, Tirzepatide and Retatrutide
  • Paired work with Garetosmab to dissect two TGF-beta superfamily ligands in one model
  • Comparative work against growth-factor-driven approaches such as IGF-1 LR3 and PEG-MGF, which stimulate anabolic signalling rather than removing a brake on it
  • Antibody handling, formulation and stability method development

How is an antibody tested differently from a peptide?

This is where most listings for this compound fall down, so it is worth reading before comparing certificates.

A peptide certificate is built on reversed-phase HPLC purity, an ESI-MS charge state and Karl Fischer water content. None of those are valid for a 144 kDa glycoprotein. Reversed-phase conditions denature the antibody, a single-charge-state mass is meaningless against a glycan-heterogeneous population, and water content says nothing about the impurities that matter.

The antibody panel replaces it:

  • Monomer purity (SEC-HPLC): aggregation is the primary quality risk for an antibody
  • Aggregate content (SEC-HPLC): quantified separately from the monomer peak
  • Identity and chain integrity (SDS-PAGE, reduced and non-reduced): ~150 kDa intact; ~50 kDa heavy and ~25 kDa light on reduction
  • Identity (deglycosylated intact mass): the mass check that works on a glycosylated protein
  • Binding activity (ELISA against immobilised target): an antibody that is pure but not active is a failed lot
  • Selectivity (counter-screen against the lookalike ligand): the property the compound is bought for
  • Endotoxin (LAL): mammalian cell culture product
  • Concentration (UV A280): reported, not assumed

If a supplier hands you a reversed-phase HPLC trace and a Karl Fischer number for a monoclonal antibody, that certificate was written for a different kind of molecule.

Handling and storage

Antibodies fail differently from peptides. The dominant failure mode is aggregation, driven by agitation, freeze-thaw cycling and air-liquid interface exposure, not the hydrolysis and oxidation that degrade peptides.

  • Lyophilized, unopened: 2 to 8 degrees Celsius, 24 months
  • Reconstitute gently: add diluent down the vial wall and swirl. Never vortex, never shake. Foaming denatures antibody at the air-liquid interface
  • Reconstituted: 2 to 8 degrees Celsius up to 4 weeks, or single-use aliquots at minus 80 degrees Celsius
  • Aliquot before freezing: repeated freeze-thaw is the single largest driver of aggregate formation

Quality standards

  • Monomer purity: 98 percent or greater by SEC-HPLC, aggregates reported separately
  • Expression system: CHO mammalian cell culture, Protein A purified
  • Endotoxin: less than 1.0 EU/mg by LAL
  • Form: lyophilized from a histidine and sucrose matrix in single-use vials
  • Documentation: batch-matched antibody Certificate of Analysis published at /lab-results
  • Fill strengths: 0.1 mg, 1 mg, 5 mg, 10 mg and 100 mg, priced per vial

For laboratory research purposes only. Not for human consumption, therapeutic use, or any in vivo application in humans. Trevogrumab is an investigational compound and is not approved as a medicine in any jurisdiction.

Research Context for Trevogrumab

Muscle Growth and Anabolic Research Context

Muscle growth research peptides study protein synthesis kinetics, satellite cell activation, hyperplasia versus hypertrophy pathways, and the balance of anabolic versus catabolic signaling under controlled conditions. These protocols often involve combination work with growth hormone secretagogues or IGF analogs to probe mechanistic independence.

Trevogrumab ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Growth hormone category, with 5 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation on this batch's Certificate of Analysis, published for the batch we're shipping now. Every released batch is listed on the lab results page.

Research Tools for This Compound

Frequently Asked Questions

What is Trevogrumab?

Trevogrumab (development code REGN1033, CAS 1429201-24-0) is a fully human IgG4-kappa monoclonal antibody that binds and neutralises myostatin, also known as growth differentiation factor 8 or GDF-8. It was generated by Regeneron on the VelocImmune platform with Sanofi as a development partner. Molecular formula C6374H9884N1696O2018S46, molar mass 144,037.80 g/mol, approximately 144 kDa. It is expressed in CHO mammalian cell culture and purified by Protein A affinity chromatography. It is supplied here as a research reference standard only.

Is Trevogrumab a peptide?

No. Trevogrumab is a monoclonal antibody, not a peptide, and several vendors list it incorrectly. It is a four-chain immunoglobulin of approximately 144 kDa, roughly thirty times the mass of a peptide like BPC-157, built from two heavy chains and two light chains with interchain disulfide bonds and N-linked glycosylation. Solid-phase peptide synthesis cannot produce a molecule of this size or architecture; it requires recombinant expression in mammalian cell culture. The distinction is not academic: it determines how the material is tested, stored and handled, and it is why the Certificate of Analysis uses SEC-HPLC and SDS-PAGE rather than the reversed-phase HPLC panel used for peptides.

How much does Trevogrumab cost?

Trevogrumab is priced per single vial, not per 10-vial kit like the peptide catalogue, and five fill strengths are available: 0.1 mg from $720, 1 mg from $1,255, 5 mg from $3,295, 10 mg from $4,185 and 100 mg from $8,895. The standard quantity discount ladder applies per vial ordered, reaching 42 percent off at the deepest tier, so 50 vials of the 100 mg fill price at $5,160 each. Live pricing in your local currency is shown on this page. Antibody production costs an order of magnitude more per milligram than peptide synthesis, which is why these sit well above the rest of the catalogue.

Why does the lack of GDF11 cross-reactivity matter?

Because most myostatin research tools cannot distinguish the two. Soluble ActRIIB-Fc decoy receptors bind myostatin, GDF11, activin A and several BMPs simultaneously, so any observed phenotype is the sum of all of them and cannot be attributed afterwards. An antibody selective for myostatin over GDF11 allows a research model to assign an effect to a single ligand. If your study design depends on that attribution, this selectivity is the reason to choose Trevogrumab over a decoy receptor construct.

What did the COURAGE trial show?

COURAGE (NCT06299098) is Regeneron's Phase 2 study of semaglutide with trevogrumab, with or without garetosmab, presented at EASD 2025. About a third of the weight lost on semaglutide alone was lean mass. At 26 weeks, lean mass fell 6.5% on semaglutide alone, 3.3% to 3.8% with trevogrumab added, and 2.0% with both antibodies added. The triple combination had more discontinuations for tolerability.

What testing appears on the Trevogrumab Certificate of Analysis?

The antibody release panel: monomer purity and aggregate content by SEC-HPLC; identity and chain integrity by SDS-PAGE reduced and non-reduced; identity by deglycosylated intact mass on LC-ESI-QTOF MS; target binding activity by ELISA; a GDF11 selectivity counter-screen; protein concentration by UV A280; bacterial endotoxins by kinetic chromogenic LAL; plus appearance and pH. A reversed-phase HPLC purity figure and a Karl Fischer water content, which is what a peptide certificate carries, would be the wrong tests for this molecule.

How should Trevogrumab be reconstituted and stored?

Store the lyophilized vial at 2 to 8 degrees Celsius; it is stable for 24 months unopened. Reconstitute by adding diluent slowly down the inner wall of the vial and swirling gently until dissolved. Never vortex and never shake: antibodies denature at the air-liquid interface and foaming drives aggregate formation. Reconstituted material is stable for up to 4 weeks at 2 to 8 degrees Celsius, or aliquot into single-use volumes and store at minus 80 degrees Celsius. Always aliquot before freezing, because repeated freeze-thaw cycling is the largest single driver of aggregation in antibody preparations.

What is the clinical development status of Trevogrumab?

Trevogrumab is investigational and is not approved as a medicine in any jurisdiction. Regeneron is evaluating it in the Phase 2 COURAGE study (NCT06299098) in combination with semaglutide for lean mass preservation during weight loss in obesity, with results presented at EASD 2025. Material supplied here is a research reagent and is unrelated to any clinical supply chain. It is not for human use.

1 vial

$720